机构:[1]Department of Internal Medicine/Oncology, Academic Natters Hospital, Natters, Austria[2]Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing, China血液科[3]Clinical Pathology, Paracelsus Private Medical University of Salzburg, Salzburg, Austria[4]Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria
第一作者机构:[1]Department of Internal Medicine/Oncology, Academic Natters Hospital, Natters, Austria[2]Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing, China
通讯作者:
通讯机构:[1]Department of Internal Medicine/Oncology, Academic Natters Hospital, Natters, Austria[*1]Department of Internal Medicine, Academic Natters Hospital, In der Stille 20, 6161 Natters, Austria.
推荐引用方式(GB/T 7714):
W. L. Sun,G. Hutarew,J. Gradl,et al.Bevacizumab-based combination therapy in a patient with pseudomyxoma peritonei[J].Memo - Magazine of European Medical Oncology.2009,2(2):doi:10.1007/s12254-009-0113-y.
APA:
W. L. Sun,G. Hutarew,J. Gradl,M. Gratzl,E. Heumader...&M. Fiegl.(2009).Bevacizumab-based combination therapy in a patient with pseudomyxoma peritonei.Memo - Magazine of European Medical Oncology,2,(2)
MLA:
W. L. Sun,et al."Bevacizumab-based combination therapy in a patient with pseudomyxoma peritonei".Memo - Magazine of European Medical Oncology 2..2(2009)